Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Novel LXR agonist as well as preparation method and application thereof

A kind of use, the technology of medicinal salt, applied in the field of new compounds, can solve the problem of not being able to regulate the expression of human CYP7A1 gene

Inactive Publication Date: 2009-06-17
NCPC NEW DRUG RES & DEV
View PDF3 Cites 34 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the human CYP7A1 gene does not contain LXRE, so LXR cannot regulate the expression of the human CYP7A1 gene

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel LXR agonist as well as preparation method and application thereof
  • Novel LXR agonist as well as preparation method and application thereof
  • Novel LXR agonist as well as preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0063] The cultivation of embodiment 1 bacterial classification

[0064] Slant medium: PDA medium.

[0065] Seed medium: starch 2%, glucose 1%, hot-pressed soybean cake powder 0.2%, malt powder 0.6%, yeast powder 0.3%, NaCl 0.2%, MgSO 4· 7H 2 O 0.1%, CaCO 3 0.2% pH 7.0.

[0066] Fermentation medium: The rice medium is 2.5g of soybean flour per 100g of rice.

[0067] The slant of the fungus CGMCC No.2037 was inoculated in the seed medium, and after 72hr cultivation at 27°C, it was inserted into a 750ml Erlenmeyer flask with a content of 100g of rice medium, and cultivated in a solid medium for 14 days.

Embodiment 2

[0068] Example 2 Isolation and structure of compounds (I), (II) and (III)

[0069] CGMCC No.2037 solid culture 4kg, soaked in 4000ml ethyl acetate for 2 hours, the ethyl acetate layer was washed with anhydrous Na 2 SO 4 After dehydration, concentration and drying, 23.0 g of brown substance was obtained.

[0070] Take 22.0g sample, dissolve and mix the sample, carry out silica gel medium pressure column (φ3.5×50cm) chromatographic separation, the elution condition is 100% petroleum ether to 100% acetone (different ratio) stage elution, collect and combine activity Components were concentrated and dried to obtain a brown solid.

[0071] Take the above-mentioned active substances, use ODS reverse phase column (PHENOMENEX ODS φ 21.2×250mm) to carry out single-component preparation on preparative HPLC [mobile phase is CH 3 CN-(1‰H 3 PO 4 )H 2 O(80:40), the flow rate is 16ml / min, and the detection wavelength is 254nm] to obtain 256.2mg of compound (I), 30.0mg of compound (II) ...

Embodiment 3

[0090] Example 3 Agonistic activity on LXR

[0091] This activity assay is an assay for the transcriptional activation of GAL4-LXR:

[0092] Assay principle: This mechanism utilizes the two main structural domains shared in the structure of LXR: the independence of the ligand-binding domain (LBD) and the DNA-binding domain (DBD) function, and the yeast cell transcription factor GAL4 has a nuclear receptor The ligand-binding domain (LBD) of LXR was fused with the DNA-binding domain (DBD) of yeast cell transcription factor GAL4 to express a chimeric protein, which was co-transfected with a reporter plasmid containing a GAL4-specific response element , to evaluate the activity of LXR ligands by measuring the expression of the reporter gene. According to this principle, the expression plasmid and reporter plasmid were constructed: the LXR-LBD fragment amplified by PCR from liver tissue was connected to the expression vector pBIND by double enzyme digestion to construct the pBIND-...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to novel compounds as LXR receptor stimulating agents and a medicament composition containing the compounds or pharmaceutically acceptable salt thereof and also relates to a method for preparing the compounds and the medicament composition thereof. The invention discloses application of the compounds as pharmacological active substances, in particular application in treating cardiovascular diseases such as hypertension, hyperlipemia, hypercholesterolemia, atherosclerosis and coronary heart disease, as well as inflammation, adiposis, diabetes, metabolic syndrome and the like.

Description

technical field [0001] The present invention relates to a new class of compounds, in particular to agonists of the liver X receptor. Background technique [0002] Liver X-activated receptors (LXRs) were initially reported by Willy in 1995 as a regulator of cholesterol metabolism, and were named because they are most abundantly expressed in the liver [Genes Dev.1995May 1; 9(9): 1033-45] . LXRs are members of the nuclear receptor superfamily, including LXRα (NR1H3) and LXRβ (NR1H2), with 77% homology and the same endogenous ligands. LXRβ is widely expressed, while LXRα is mainly distributed in the liver, adipose tissue, small intestine and macrophages. After LXRs are activated by ligands, they first form LXR / RXR heterodimers with retinoid receptor α (retinoid X re-ceptora), and then bind to the specific LXR response element (LXRE) on the target gene. Regulate the expression of this gene. LXRE is a repeating sequence composed of AGGTCA, with 4 bases in between [J BiolChem, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D491/14C07D487/14A61K31/519A61P9/00A61P29/00A61P3/06A61P3/04A61P3/10C12P15/00C12R1/66
Inventor 路新华郑智慧李业英可爱兵马瑛崔晓兰石英朱京童任晓林洁丁彦博穆栋徐岩曹林张雪莲单越琦蔡超静范玉玲张华贺建功
Owner NCPC NEW DRUG RES & DEV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com